Retrospectively monitoring CALR/HSP expression in formalin-fixed paraffin-embedded bioptic samples from cancer patients by immunohistochemistry coupled to the evaluation of clinicopathological variables, offers a tool to estimate the impact of CALR/HSP exposure on disease progression91,146. The gene discussed is CALR; the disease is cancer.